Looking to unseat Sanofi and Shire drugs, Atlas gene therapy startup Avrobio files for $86M IPO

Avrobio has filed for an $86.25 million IPO. The offering would give the Atlas Venture-backed startup the means to run clinical trials of gene therapies designed to supplant enzyme replacement therapi…
Read the full story: FierceBiotech: Biotech